Launch of our new ELISA range - World’s First: Bispecific Antibody Drug ELISA

We are proud to announce the launch of our new range of products: Bispecific Antibody Drug ELISA kits for quantifying bispecific antibodies in serum and plasma samples.

Bispecific antibodies, as the name suggests, are antibodies that target two targets or epitopes simultaneously. In 2022, they have quickly gained ground amongst scientists and pharmaceutical manufacturers with the approval of four different BsAb drugs by the US FDA and EMA for therapeutic use. Currently, these bsAbs are targeted towards cancer targets, particularly CD3 pathways.

Krishgen’s range of bispecific antibody ELISA are the first of their kind in the world, posing a standardized, ready-to-use and well validated solution to the research and development of new drugs.

This range of products spans 40+ targets in a standard, 96 well format ELISA kit.